# Nuclide record everolimus (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/everolimus/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "everolimus" ;
  schema:name "Everolimus"@en ;
  schema:description "An mTOR-blocking pill that doubled progression-free time with exemestane in 2012 and is now paired with the oral SERD giredestrant."@en ;
  schema:url <https://nuclide.cc/drugs/everolimus/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Everolimus> ;
  owl:sameAs <http://www.wikidata.org/entity/Q421052> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Everolimus> ;
  nuclide:status "approved" ;
  nuclide:modality "Small-molecule mTOR inhibitor" ;
  schema:alternateName "Afinitor" ;
  nuclide:approval "US 2012: HR+/HER2- advanced breast cancer with exemestane after NSAI failure", "US 2011: Progressive pancreatic NETs", "US 2016: Progressive non-functional lung and GI NETs", "US 2009: Advanced RCC after sunitinib or sorafenib" ;
  nuclide:indications <https://nuclide.cc/indications/rcc/>, <https://nuclide.cc/indications/neuroendocrine/> ;
  nuclide:companies <https://nuclide.cc/companies/novartis/> ;
  nuclide:trials <https://nuclide.cc/trials/nct04919226/>, <https://nuclide.cc/trials/radiant-3-4/>, <https://nuclide.cc/trials/compete/> .